Transcript
Page 1: Viral vaccines Current Practices

DR.T.V.RAO MD 1

Dr.T.V.Rao MD

VIRAL VACCINES

CURRENT PRACTICES

Page 2: Viral vaccines Current Practices

DR.T.V.RAO MD 2

WHAT ARE VIRUSES• Viruses are intracellular parasites unable to survive without

a living host

• Non-living ?; do not follow Koch’s Postulates

• They cannot reproduce or metabolize on their own because they lack the self-machinery to do so Obligatory replicate inside host cells using host metabolism

• A single infectious virus particle is termed a Virion that acts as the vehicle for transmission

• All viruses consist of either double- or single-stranded DNA or RNA that is linear or circular (or fragmented)

Page 3: Viral vaccines Current Practices

DR.T.V.RAO MD 3

VIRUSES• A virus is a submicroscopic obligate parasitic particle that infects

cells in biological organisms.

• Viruses are non-living particles that can only replicate when an organism reproduces the virulent RNA or DNA.

• Among other things, viruses do not move, metabolize, or decay on their own. Viruses are obligate intracellular parasites that lack the cellular machinery for self-reproduction.

• Viruses infect eukaryotes and prokaryotes such as bacteria; bacteriophages.

• Typically viruses carry a small amount of genetic material, either in the form of RNA or DNA, but not both, surrounded by some form of protective coat consisting of proteins, lipids, glycoproteins or a combination.

• The viral genome codes for the proteins that constitute this protective coat, as well as for those proteins required for viral reproduction that are not provided by the host cell.

Page 4: Viral vaccines Current Practices

DR.T.V.RAO MD 4

HISTORICAL BEGINNING Smallpox was the first disease people tried to prevent by purposely inoculating themselves with other types of infections. Inoculation is believed to have started in India or China before 200 BC. Physicians in China immunized patients by picking off pieces from drying pustules of a person suffering from a mild case of smallpox, grinding the scales to a powdery substance, and then inserting the powder into the person's nose in order for them to be immunized. In 1718, Lady Mary Wortley Montague reported that the Turks have a habit of deliberately inoculating themselves with fluid taken from mild cases of smallpox. Lady Montague inoculated her own children in this manner

Page 5: Viral vaccines Current Practices

DR.T.V.RAO MD 5

ORIGIN OF VACCINES In 1796, during the heyday of the smallpox virus in Europe, an English country doctor, Edward Jenner, observed that milkmaids would sometimes become infected with cowpox through their interactions with dairy cows' udders. Cowpox is a mild relative of the deadly smallpox virus. Building on the foundational practice of inoculation, Jenner took infectious fluid from the hand of milkmaid Sarah Nelmes. He inserted this fluid, by scratching or injection, into the arm of a healthy local eight year old boy, James Phipps. Phipps then showed symptoms of cowpox infection. Forty-eight days later, after Phipps had fully recovered from cowpox, Jenner injected some smallpox-infected matter into Phipps, but Phipps did not later show signs of smallpox infection

Page 6: Viral vaccines Current Practices

DR.T.V.RAO MD 6

BASIC STRATEGIES IN VACCINATION

Page 7: Viral vaccines Current Practices

DR.T.V.RAO MD 7

VACCINES [BACKGROUND]• Vaccine comes from the Latin word “vacca” which pertains to

“cows”

• Based on the practice of variolation which was inoculating healthy individuals with weak forms of smallpox

• 1st Vaccine (1796): Edward Jenner inoculated milkmaids with cowpox to confer protective immunity against smallpox.

• 1st Attenuated Vaccine (1885): Louis Pasteur developed a vaccine to protect against rabies; vaccine is made from viable virus with reduced virulence (lower degree of pathogenicity).

Page 8: Viral vaccines Current Practices

DR.T.V.RAO MD 8

VACCINES [BACKGROUND]• Most damage to a cell is done too early before any clinical

symptoms of disease appear. Treatment becomes difficult, therefore, prevention is preferred over post-exposure vaccines.

• The Main Idea: Vaccines contain a weak form of a virus/microbe that is not pathogenic

• Vaccines are used to protect a large number of people – fight against epidemics and pandemics.

• Good vaccines elicit a secondary immune response that will eliminate the pathogen.

Page 9: Viral vaccines Current Practices

DR.T.V.RAO MD 9

TIMELINE OF VACCINES• 18th century

• 1796 First vaccine for smallpox, first vaccine for any disease

• 19th century

• 1882 First vaccine for rabies

• 20th century

• 1932 First vaccine for yellow fever

• 1945First vaccine for influenza

• 1952 First vaccine for polio

• 1954 First vaccine for Japanese encephalitis

• 1957 First vaccine for adenovirus-4 and 7

Page 10: Viral vaccines Current Practices

DR.T.V.RAO MD 10

TIMELINE OF VACCINES• 1962 First oral polio vaccine

• 1964 First vaccine for measles

• 1967 First vaccine for mumps

• 1970 First vaccine for rubella

• 1974 First vaccine for chicken pox

• 1977 First vaccine for pneumonia

• 1978 First vaccine for meningitis

• 1981 First vaccine for hepatitis B

• 1992 First vaccine for hepatitis A

• 1998 First vaccine for rotavirus

Page 11: Viral vaccines Current Practices

DR.T.V.RAO MD 11

VACCINES BASICS• The principle of vaccination is to induce a "primed" state in the vaccinated subject so that, following

exposure to a pathogen, a rapid secondary immune response is generated leading to the accelerated elimination of the organism and protection from clinical disease. Success depends on the generation of memory T and B cells and the presence in the serum of neutralizing antibody.

• Attributes of a good vaccine

• 1.Ability to elicit the appropriate immune response for the particular pathogen:

• Tuberculosis - cell mediated response

• most bacterial and viral infections - antibody

• 2. Long term protection ideally life-long3. Safety vaccine itself should not cause disease4. Stable retain immunogenicity, despite adverse storage conditions prior to administration5. Inexpensive

Page 12: Viral vaccines Current Practices

DR.T.V.RAO MD 12

VACCINES IMITATE AN INFECTION

• Vaccines contain a weakened form of the microbe that doesn’t cause disease or reproduce

• Vaccines stimulate the macrophages, which present the antigens to T and B cells

• The mock infection is rapidly cleared, and you are left with a supply of memory T cells and B cells to protect you against of future infection of this type

Page 13: Viral vaccines Current Practices

DR.T.V.RAO MD 13

Page 14: Viral vaccines Current Practices

DR.T.V.RAO MD 14

Page 15: Viral vaccines Current Practices

DR.T.V.RAO MD 15

THE IMMUNE SYSTEM & RESPONSE AND VACCINES

• Once vaccinated, the immune system takes a week and upwards to begin fighting off the organism.

• Immunity is conferred once the immune system is “trained” to resist a certain disease a vaccine is developed for

• Artificially Acquired Immunity is provided

• Childhood vaccinations are highly encouraged against:

• Measles, Mumps, Rubella, Polio, Hepatitis A & B, Diphtheria, Pertussis, Tetanus, Chicken Pox, HIB, Rotavirus, Meningococcal disease, and Influenza.

Page 16: Viral vaccines Current Practices

DR.T.V.RAO MD 16

THE IMMUNE SYSTEM & RESPONSE

• Macrophages: white blood cells that detect and engulf viral antigens; microbes are carried to lymphocytes

• Within lymph nodes, T and B cells are activated

• T cells: able to recognize virus infected cells early in infection period and release cytotoxins to destroy them

• B cells: secrete antibodies that bind antigens on the virus surface. This coats the virus and prevents infection. B-cells can also recognize virus infected cells late in infection Ideally, good vaccines evoke both T and B cells

• Antibodies will activate macrophages to “engulf ” viral antigens

Page 17: Viral vaccines Current Practices

DR.T.V.RAO MD 17

VACCINE TYPES

Page 18: Viral vaccines Current Practices

DR.T.V.RAO MD 18

LIVE (ATTENUATED) VACCINES

• Consist of a live form of the virus that has been artificially weakened; select for mutants that will cause wild-type infection without onset of disease

• Usually only takes 1 or 2 doses to confer life long immunity (childhood vaccines).

• Must be careful of the small chance of reversion to a more virulent form

• Elicit good immune response, inexpensive, but must be cautiously stored to maintain viability

Page 19: Viral vaccines Current Practices

DR.T.V.RAO MD 19

INACTIVATED VACCINES

• Using heat, radiation or chemicals a virus is killed and is no longer infectious

• WHY USE AN INACTIVATED VIRUS?

• Attenuated strains have yet to be developed

• Reversion to virulent forms is a high occurrence

• Requires no refrigeration

• The downside is that the immunogenicity is lowered and multiple doses will be required (i.e. booster shots)

• Adjuvants: administered simultaneously to enhance immune response

• Combination vaccines: DTP and MMR

• More expensive to prepare

Page 20: Viral vaccines Current Practices

DR.T.V.RAO MD 20

VACCINES IN GENERAL USE

Measles • Live attenuated virus grown in chick embryo

fibroblasts, first introduced in the 1960's. Its extensive use has led to the virtual eradication of measles in the first world. In developed countries, the vaccine is administered to all children in the second year of life (at about 15 months). However, in developing countries, where measles is still widespread, children tend to become infected early (in the first year), which frequently results in severe disease. It is therefore important to administer the vaccine as early as possible (between six months and a year). If the vaccine is administered too early, however, there is a poor take rate due to the interference by maternal antibody. For this reason, when vaccine is administered before the age of one year, a booster dose is recommended at 15 months.

Page 21: Viral vaccines Current Practices

DR.T.V.RAO MD 21

VACCINES IN GENERAL USEMumps • Live attenuated virus developed in the 1960's.  

In first world countries it is administered together with measles and rubella at 15 months in the MMR vaccine.

• The current "Jeryl Lynn" strain of the mumps vaccine was developed by Dr. Maurice Hillman from the mumps virus that infected his 5-year-old daughter (whose name was Jeryl Lynn). This vaccine, combined with rubella or both rubella and measles vaccines (MMR), has been widely used worldwide (300 million doses given) since it was approved by the FDA in 1967.

Page 22: Viral vaccines Current Practices

DR.T.V.RAO MD 22

VACCINES IN GENERAL USE

Polio • Two highly effective vaccines containing all 3 strains of poliovirus are in

general use: • The killed virus vaccine (Salk, 1954) is used mainly in Sweden, Finland,

Holland and Iceland. • The live attenuated oral polio vaccine (Sabin, 1957) has been adopted in

most parts of the world;  its chief advantages being: low cost, the fact that it induces mucosal immunity and the possibility that, in poorly immunized communities, vaccine strains might replace circulating wild strains and improve herd immunity.  Against this is the risk of reversion to virulence (especially of types 2 and 3) and the fact that the vaccine is sensitive to storage under adverse conditions. - Orimune®

• The inactivated Salk vaccine is recommended for children who are immunosuppressed.

• 3 types of live polio virus, magnesium chloride, amino acid, polysorbate 80, purified water, neomycin, sulphate, streptomycin, penicillin and monkey kidney cell cultures.

Page 23: Viral vaccines Current Practices

DR.T.V.RAO MD 23

VACCINES IN GENERAL USE

Rubella • Live attenuated virus. Rubella causes a mild febrile illness in

children, but if infection occurs during pregnancy, the fetus may develop severe congenital abnormalities. Two vaccination policies have been adopted in the first world. In the USA, the vaccine is administered to all children in their second year of life (in an attempt to eradicate infection), while in Britain, until recently, only post pubertal girls were vaccinated.  It was feared that if the prevalence of rubella in the community fell, then infection in the unimmunized might occur later - thus increasing the likelihood of infection occurring in the child-bearing years.  This programme has since been abandoned in Britain and immunization of all children is the current practice.

• MMR — live measles virus, live mumps virus, live rubella virus, chick embryo, human foetal cells, neomycin, sorbitol, gelatine.

Page 24: Viral vaccines Current Practices

DR.T.V.RAO MD 24

VACCINES IN GENERAL USERabies • No safe attenuated strain of rabies virus has yet been developed for humans.

Vaccines in current use include:

• The neurotissue vaccine - here the virus is grown in the spinal cords of rabbits, and then inactivated with beta-propiolactone. There is a high incidence of neurological complications following administration of this vaccine due to a hypersensitivity reaction to the myelin in the preparation and largely it has been replaced by

• A human diploid cell culture-derived vaccine (also inactivated) which is much safer.

There are two situations where vaccine is given: a) Post-exposure prophylaxis, following the bite of a rabid animal:A course of 5-6 intramuscular injections, starting on the day of exposure. Hyperimmune rabies globulin may also administered on the day of exposure.

• b) Pre-exposure prophylaxis is used for protection of those whose occupation puts them at risk of infection with rabies;  for example, vets, abbatoir and laboratory workers. This schedule is 2 doses one month apart ,and a booster dose one year later. (Further boosters every 2-3 years should be given if risk of exposure continues).

Page 25: Viral vaccines Current Practices

DR.T.V.RAO MD 25

VACCINES IN GENERAL USEInfluenza • Repeated infections with influenza virus are common due to rapid

antigenic variation of the viral envelope glycoproteins. Antibodies to the viral neuraminidase and haemagglutinin proteins protect the host from infection.   However, because of the rapid  antigenic variation, new vaccines, containing antigens derived from influenza strains currently circulating in the community, are produced every year.   Surveillance of influenza strains now allows the inclusion of appropriate antigens for each season.The vaccines consist of partially purified envelope proteins of inactivated current influenza A and B strains.

• Individuals who are at risk of developing severe, life threatening disease if infected with influenza should receive vaccine.   People at risk include the elderly, immunocompromised individuals, and patients with cardiac disease. In these patients, protection from disease is only partial, but the severity of infection is reduced.

Page 26: Viral vaccines Current Practices

DR.T.V.RAO MD 26

VACCINE IN SPECIAL CIRCUMSTANCES

• Varicella-Zoster virus

• A live attenuated strain of varicella zoster virus has been developed. It is not licensed in South Africa for general use, but is used in some oncology units to protect immuno-compromised children who have not been exposed to wild-type varicella zoster virus. Such patients may develop severe, life threatening infections if infected with the wild type virus.

Page 27: Viral vaccines Current Practices

DR.T.V.RAO MD 27

VACCINES IN SPECIAL CIRCUMSTANCES

Yellow Fever

• The 17D strain is a live attenuated vaccine developed in 1937. It is a highly effective vaccine which is administered to residents in the tropics and travelers to endemic areas. A single dose induces protective immunity to travelers and booster doses, every 10 years, are recommended for residents in endemic areas.

Page 28: Viral vaccines Current Practices

DR.T.V.RAO MD 28

HEPATITIS B VACCINATION EMERGING NEED IN VACCINATION

• Hepatitis B • Two vaccines are in current use: a serum derived vaccine and a

recombinant vaccine. Both contain purified preparations of the hepatitis B surface protein.

• The serum derived vaccine is prepared from hepatitis B surface protein, purified from the serum of hepatitis B carriers. This protein is synthesised in vast excess by infected hepatocytes and secreted into the blood of infected individuals. A vaccine trial performed on homosexual men in the USA has shown that, following three intra-muscular doses at 0, 1 and 6 months, the vaccine is at least 95% protective.

Page 29: Viral vaccines Current Practices

DR.T.V.RAO MD 29

NEWER VACCINES FOR HEPATITIS B INFECTIONS

• A second vaccine, produced by recombinant DNA technology, has since become available. Previously, vaccine administration was restricted to individuals who were at high risk of exposure to hepatitis B, namely: infants of hepatitis B carrier mothers, health care workers, homosexual men and intravenous drug abusers. However, hepatitis B has been targetted for eradication , and since 1995 the vaccine has been included in the universal childhood immunization schedule. Three doses are given; at 6, 10, and 14 weeks of age. As with any killed viral vaccines, a booster will be required at some interval (not yet determined, but about 5 years) to provide protection in later life from hepatitis B infection as a venereal disease.

• HEPATITIS B — Hepatitis B virus gene, aluminium hydroxide, mercury, formaldehyde. For the genetically engineered vaccine: aluminium hydrochloride, sodium chloride and mercury

Page 30: Viral vaccines Current Practices

DR.T.V.RAO MD 30

ROTATEQ AND ROTAVIRUS INFECTIONS

• Rotateq is a live, oral Pentavalent vaccine that contains five rotaviruses produced by reassortment. The rotavirus A parent strains of the reassortants were isolated from human and bovine hosts. Four reassortant rotaviruses express one of the outer capsid, VP7, proteins (serotypes G1, G2, G3, or G4) from the human rotavirus parent strain and the attachment protein VP4 (type P7) from the bovine rotavirus parent strain. The fifth reassortant virus expresses the attachment protein VP4, (type P1A), from the human rotavirus parent strain and the outer capsid protein VP7 (serotype G6) from the bovine rotavirus parent strain. In February 2006 approved RotaTeq for use in the United States.

Page 31: Viral vaccines Current Practices

DR.T.V.RAO MD 31

WHO RECOMMENDS THE ROTAVIRUS VACCINE

• WHO recommends that rotavirus vaccine for infants should be included in all national immunization programmes. In countries where diarrhoeal deaths account for ≥10% of mortality among children aged <5 years, the introduction of the vaccine is strongly recommended. WHO recommends that the first dose of either RotaTeq or Rotarix be administered at age 6–15 weeks. The maximum age for administering the last dose of either vaccine should be 32 weeks.

Page 32: Viral vaccines Current Practices

DR.T.V.RAO MD 32

HPV – HUMAN PAPILLOMAVIRUS

• Genital HPV most common sexually transmitted infection in US

• Cause of cervical cancer, genital warts, anal & penile cancer

• By the age of 50, 80% of women will have contracted at least 1 strain of the virus

• Fortunately, many strains can be cleared by immune system before symptoms occur

• HPV vaccine is a preventative measure against initial infection

Page 33: Viral vaccines Current Practices

DR.T.V.RAO MD 33

HPV – HUMAN PAPILLOMAVIRUS

• HPV – Human Papillomavirus

• Types 16 and 18 cause 70% of the cases of cervical cancer and types 6 and 11 cause 90% of genital warts

• HPV Vaccine, Gardasil, protects against these strains

• Pap smears are still recommended since there are over 100 HPV strains identified, many of which can also cause cancer

Page 34: Viral vaccines Current Practices

DR.T.V.RAO MD 34

SUBUNIT VACCINES • Immune response can be stimulated by one or a set of viral

proteins.

• This was first demonstrated by hepatitis B and influenza vaccines

• These can be a lot safer than attenuated or inactivated vaccines

• The subunits included are determined by identifying which proteins the antibodies recognize.

• Subunits vaccines

• Composed solely of purified protein can be delivered to body by means of a non-pathogenic virus, bacteria, etc

Page 35: Viral vaccines Current Practices

DR.T.V.RAO MD 35

DNA VACCINES• DNA vaccines are at present experimental, but hold promise for future therapy since they will

evoke both Humoral and cell-mediated immunity, without the dangers associated with live virus vaccines.

• The gene for an antigenic determinant of a pathogenic organism is inserted into a plasmid. This genetically engineered plasmid comprises the DNA vaccine which is then injected into the host. Within the host cells, the foreign gene can be expressed (transcribed and translated) from the plasmid DNA, and if sufficient amounts of the foreign protein are produced, they will elicit an immune response. in recent years a new type of vaccine, created from an infectious agent's DNA called DNA vaccination, has been developed. It works by insertion (and expression, triggering immune system recognition) into human or animal cells, of viral or bacterial DNA. These cells then develop immunity against an infectious agent, without the effects other parts of a weakened agent's DNA might have. As of 2006, DNA vaccination is still experimental, but shows some promising results .

Page 36: Viral vaccines Current Practices

DR.T.V.RAO MD 36

RECOMBINANT VACCINES • Recombinant vaccines are those in which genes for desired antigens are

inserted into a vector, usually a virus, that has a very low virulence.

• The vector expressing the antigen may be used as the vaccine, or the antigen may be purified and injected as a subunit vaccine.

• The only recombinant vaccines currently in use in humans is the Hepatitis B Virus (HBV) vaccine, and HPV which is a recombinant subunit vaccine

• Hepatitis B surface antigen is produced from a gene transfected into yeast cells and purified for injection as a subunit vaccine.

• This is much safer than using attenuated HBV, which could cause lethal hepatitis or liver cancer if it reverted to its virulent phenotype.

• Recombinant DNA techniques can also be used to make safer attenuated pathogen vaccines….

Page 37: Viral vaccines Current Practices

DR.T.V.RAO MD 37

VACCINES – A METHOD OF PREVENTION

• Influenza

• Nearly 40,000 deaths and 115,000 hospitalized yearly in US

• Educated guess on most probable form of virus

• Also comes in nasal spray of attenuated form

• New vaccines must always be produced due to high antigenic variation

• At risk individuals (elderly, Immunodeficient) should be vaccinated

Page 38: Viral vaccines Current Practices

DR.T.V.RAO MD 38

HUMAN IMMUNODEFICIENCY VIRAL VACCINES

• Currently in use: subunit, recombinant, and DNA vaccines

• Method:

• Inhibit fusion to host cell

• Inhibit reverse transcriptase

• Stops any viral integration into host cells

• Targets functional HIV viral proteins

• Viral exit form host cell is stopped

• HIV continuously mutates and recombines to escape effects of vaccine

• It can also be transmitted as a free virus

Page 39: Viral vaccines Current Practices

DR.T.V.RAO MD 39

WHY HIV IS A HARD TARGET

• Spread both sexually and blood so need both mucosal immune responses and systemic

• Probably transmitted both as cell-free virus and cell associated and therefore probably need both neutralizing antibody AND T-cell mediated immune response

• Worst of all, our own immune systems can’t stop the replication of the virus

• Here, the virus’s evolution is the central issue

• maybe it will never be possible to generate immune protection against the virus

• Ignoring this, for the moment, you then still would need to contend with the tremendous genetic diversity of the virus

Page 40: Viral vaccines Current Practices

DR.T.V.RAO MD 40

VACCINES – A SOURCE OF CONTROVERSY

• Some health critics say vaccination benefits are exaggerated. Claim that vaccines are not solely responsible for reducing mortality rates of any one disease.

• Opponents find that even vaccinated individuals still contract disease

• Adverse effects (although RARE) can be worse than the naturally occurring disease

• Vaccine schedules are not designed for multiple exposure to immunogens at young ages

• Some diseases and conditions (leukaemia, MS, SIDS) have increased with the use of vaccinations

• Some vaccines contain mercury, formaldehyde, neomycin, and other toxic chemical components

Page 41: Viral vaccines Current Practices

DR.T.V.RAO MD 41

Page 42: Viral vaccines Current Practices

DR.T.V.RAO MD 42

• Vaccines still most effective preventative measure you can take to protect yourself from disease

• Remains one of the most affordable methods

• Not only are you protecting yourself, you are protecting everyone around you.

DO NOT NEGLECT VACCINATION

Page 43: Viral vaccines Current Practices

DR.T.V.RAO MD 43

• Programme Created by Dr.T.V.Rao MD for Medical and Health Care Workers in the

Developing World

• Email

[email protected]


Recommended